Federal Minister of Health tables the 2025 Annual Report of the Patented Medicine Prices Review Board
Sales of patented medicines in Canada were $24.4 billion in 2025, a 10.6% increase over the year before
OTTAWA, ON, Nov. 20, 2026 /CNW/ — The Honourable Marjorie Michel, Federal Minister of Health, today tabled the 2025 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Commons.
The 2025 Annual Report reviews trends in the prices and sales of patented medicines in Canada. Sales of patented medicines in 2025 were $24.4 billion and accounted for 48% of the sales of all medicines in Canada.
The report also sets out findings on spending on pharmaceutical research and development in Canada, as well as updated information on the PMPRB’s price review and reporting activities in 2025.
The PMPRB reviews patented medicine prices to protect Canadians from any patent abuse related to excessive prices. The PMPRB also reports on Canadian pharmaceutical trends, contributing to a greater understanding of the changing landscape.
Quick Facts
- 1,086 patented medicines for human use were reported to the PMPRB in 2025, including 82 new medicine dosage forms and strengths.
- Canadian list prices were third highest amongst the PMPRB11 countries, behind the UK and Spain. Canadian prices ranked seventh highest among the 35 Organization for Economic Co-operation and Development (OECD) countries.
- Canada represented 2.1% of worldwide pharmaceutical sales in 2025, making Canada the eighth largest national market.
- Rights holders reported $1.73 billion in R&D expenditures in 2025, for an average sales-to-R&D ratio of 4.9%. This result is based on the definition of R&D outlined in the Patented Medicines Regulations.
Associated Links
2025 Annual Report of the Patented Medicine Prices Review Board (PMPRB)
Follow us on LinkedIn and X @PMPRB_CEPMB
SOURCE Patented Medicine Prices Review Board
